Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
The market expects Amicus Therapeutics (FOLD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2019. This widely-known consensus outlook is important in assessing the company’s earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 11 […]